Multimodal cancer therapy involving oncolytic Newcastle Disease Virus, autologous immune cells and bispecific antibodies

11Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

This chapter focusses on oncolytic Newcastle disease virus (NDV). It summarizes i) the peculiarities of this virus as an anti-cancer and immune stimulatory agent and ii) approaches to further harness it as a vector to combat cancer. Special emphasis is given on combining virus therapy with cell therapy and on improving tumor targeting. The review will include some of the authors work on NDV, bispecific antibodies and cell therapy as building blocks for a new perspective of multimodal cancer therapy. The broad anti-tumor immune reactivation includes innate and adaptive, tumor antigen specific and tumor antigen independent activities. © 2014 Schirrmacher and Fournier.

Cite

CITATION STYLE

APA

Schirrmacher, V., & Fournier, P. (2014). Multimodal cancer therapy involving oncolytic Newcastle Disease Virus, autologous immune cells and bispecific antibodies. Frontiers in Oncology. Frontiers Research Foundation. https://doi.org/10.3389/fonc.2014.00224

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free